Improved hepatic perfusion after iloprost infusion in patients with HCV chronic infection

A pilot study with possible therapeutic implications

Enrico Maria Zardi, Antonio Picardi, Vito Michele Fazio, Giovanni Ambrosino, Aldo Dobrina, Marzio Zullo, Danila Zennaro, Antonella Afeltra

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

We performed a pilot study to evaluate whether portal flow volume (PFV) changed in subjects with chronic hepatitis C virus (HCV) infection with respect to control patients after infusion of iloprost, a prostacyclin analog. Six subjects with chronic HCV infection and arteriopathy of the lower limbs (CHCVIA) and 4 control patients affected only by HCV infection (CHCV) were studied with color Doppler sonography. CHCVIA patients were examined before and after 3 days of iloprost infusion, and CHCV patients were examined before and after 3 days with no treatment. In each patient, PFV was obtained after calculating portal flow velocity (PV), portal diameter, and portal vein cross-sectional area. The mean difference between basal and final values of the PFV of CHCVIA patients was significant (p = 0.03), as was the difference in the PFV (final values expressed as percent of basal values) in CHCVIA patients compared with those obtained in the CHCV patients (p = 0.01). We have observed significant improvement in hepatic perfusion in CHCVIA patients compared with CHCV patients after iloprost infusion. In light of these results, we suggest some possible therapeutic implications in patients with HCV infection. Further studies are necessary to confirm this hypothesis.

Original languageEnglish
Pages (from-to)297-300
Number of pages4
JournalJournal of Interferon and Cytokine Research
Volume24
Issue number5
DOIs
Publication statusPublished - May 2004

Fingerprint

Iloprost
Virus Diseases
Hepacivirus
Perfusion
Liver
Lower Extremity
Therapeutics
Chronic Hepatitis C
Infection
Doppler Color Ultrasonography
Epoprostenol
Portal Vein

ASJC Scopus subject areas

  • Immunology
  • Virology
  • Cell Biology

Cite this

Improved hepatic perfusion after iloprost infusion in patients with HCV chronic infection : A pilot study with possible therapeutic implications. / Zardi, Enrico Maria; Picardi, Antonio; Fazio, Vito Michele; Ambrosino, Giovanni; Dobrina, Aldo; Zullo, Marzio; Zennaro, Danila; Afeltra, Antonella.

In: Journal of Interferon and Cytokine Research, Vol. 24, No. 5, 05.2004, p. 297-300.

Research output: Contribution to journalArticle

Zardi, Enrico Maria ; Picardi, Antonio ; Fazio, Vito Michele ; Ambrosino, Giovanni ; Dobrina, Aldo ; Zullo, Marzio ; Zennaro, Danila ; Afeltra, Antonella. / Improved hepatic perfusion after iloprost infusion in patients with HCV chronic infection : A pilot study with possible therapeutic implications. In: Journal of Interferon and Cytokine Research. 2004 ; Vol. 24, No. 5. pp. 297-300.
@article{6af7c1c851694daab0511197a9ea6411,
title = "Improved hepatic perfusion after iloprost infusion in patients with HCV chronic infection: A pilot study with possible therapeutic implications",
abstract = "We performed a pilot study to evaluate whether portal flow volume (PFV) changed in subjects with chronic hepatitis C virus (HCV) infection with respect to control patients after infusion of iloprost, a prostacyclin analog. Six subjects with chronic HCV infection and arteriopathy of the lower limbs (CHCVIA) and 4 control patients affected only by HCV infection (CHCV) were studied with color Doppler sonography. CHCVIA patients were examined before and after 3 days of iloprost infusion, and CHCV patients were examined before and after 3 days with no treatment. In each patient, PFV was obtained after calculating portal flow velocity (PV), portal diameter, and portal vein cross-sectional area. The mean difference between basal and final values of the PFV of CHCVIA patients was significant (p = 0.03), as was the difference in the PFV (final values expressed as percent of basal values) in CHCVIA patients compared with those obtained in the CHCV patients (p = 0.01). We have observed significant improvement in hepatic perfusion in CHCVIA patients compared with CHCV patients after iloprost infusion. In light of these results, we suggest some possible therapeutic implications in patients with HCV infection. Further studies are necessary to confirm this hypothesis.",
author = "Zardi, {Enrico Maria} and Antonio Picardi and Fazio, {Vito Michele} and Giovanni Ambrosino and Aldo Dobrina and Marzio Zullo and Danila Zennaro and Antonella Afeltra",
year = "2004",
month = "5",
doi = "10.1089/107999004323065084",
language = "English",
volume = "24",
pages = "297--300",
journal = "Journal of Interferon and Cytokine Research",
issn = "1079-9907",
publisher = "Mary Ann Liebert Inc.",
number = "5",

}

TY - JOUR

T1 - Improved hepatic perfusion after iloprost infusion in patients with HCV chronic infection

T2 - A pilot study with possible therapeutic implications

AU - Zardi, Enrico Maria

AU - Picardi, Antonio

AU - Fazio, Vito Michele

AU - Ambrosino, Giovanni

AU - Dobrina, Aldo

AU - Zullo, Marzio

AU - Zennaro, Danila

AU - Afeltra, Antonella

PY - 2004/5

Y1 - 2004/5

N2 - We performed a pilot study to evaluate whether portal flow volume (PFV) changed in subjects with chronic hepatitis C virus (HCV) infection with respect to control patients after infusion of iloprost, a prostacyclin analog. Six subjects with chronic HCV infection and arteriopathy of the lower limbs (CHCVIA) and 4 control patients affected only by HCV infection (CHCV) were studied with color Doppler sonography. CHCVIA patients were examined before and after 3 days of iloprost infusion, and CHCV patients were examined before and after 3 days with no treatment. In each patient, PFV was obtained after calculating portal flow velocity (PV), portal diameter, and portal vein cross-sectional area. The mean difference between basal and final values of the PFV of CHCVIA patients was significant (p = 0.03), as was the difference in the PFV (final values expressed as percent of basal values) in CHCVIA patients compared with those obtained in the CHCV patients (p = 0.01). We have observed significant improvement in hepatic perfusion in CHCVIA patients compared with CHCV patients after iloprost infusion. In light of these results, we suggest some possible therapeutic implications in patients with HCV infection. Further studies are necessary to confirm this hypothesis.

AB - We performed a pilot study to evaluate whether portal flow volume (PFV) changed in subjects with chronic hepatitis C virus (HCV) infection with respect to control patients after infusion of iloprost, a prostacyclin analog. Six subjects with chronic HCV infection and arteriopathy of the lower limbs (CHCVIA) and 4 control patients affected only by HCV infection (CHCV) were studied with color Doppler sonography. CHCVIA patients were examined before and after 3 days of iloprost infusion, and CHCV patients were examined before and after 3 days with no treatment. In each patient, PFV was obtained after calculating portal flow velocity (PV), portal diameter, and portal vein cross-sectional area. The mean difference between basal and final values of the PFV of CHCVIA patients was significant (p = 0.03), as was the difference in the PFV (final values expressed as percent of basal values) in CHCVIA patients compared with those obtained in the CHCV patients (p = 0.01). We have observed significant improvement in hepatic perfusion in CHCVIA patients compared with CHCV patients after iloprost infusion. In light of these results, we suggest some possible therapeutic implications in patients with HCV infection. Further studies are necessary to confirm this hypothesis.

UR - http://www.scopus.com/inward/record.url?scp=2442494942&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2442494942&partnerID=8YFLogxK

U2 - 10.1089/107999004323065084

DO - 10.1089/107999004323065084

M3 - Article

VL - 24

SP - 297

EP - 300

JO - Journal of Interferon and Cytokine Research

JF - Journal of Interferon and Cytokine Research

SN - 1079-9907

IS - 5

ER -